CAR T cell therapies have proven remarkably successful for patients with advanced blood cancers but have been less effective against solid tumors like breast and lung cancer. Dr. Srivastava seeks to change that. To better understand the challenges of treating solid tumors with CAR T cells, she has developed a lung cancer model that accurately replicates the initiation, progression, and therapeutic response of human lung cancer. She is using this model to study the effectiveness of CAR T cells designed to target the tumor-associated antigen ROR1 and identify the major immunosuppressive mechanisms that interfere with anti-tumor activity. Furthermore, she will use this model to test whether CAR T cells’ effectiveness can be enhanced when used in combination with checkpoint immunotherapy or other treatments that target the immunosuppressive tumor microenvironment.
Fred Hutchinson Cancer Research Center | All Cancers, Lung Cancer | 2017 | Stanley R. Riddell, M.D.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
This September for Childhood Cancer Awareness Month, we look at new research, new treatments, and how we are working toward a future immune to childhood cancer.
This September for Gynecologic Cancer Awareness Month, we reflect on new treatments, research discoveries, and how CRI is making its impact on a future immune to cervical, ovarian, and uterine cancers.